SVT 6A479
Alternative Names: SVT-6A479Latest Information Update: 26 Oct 2021
At a glance
- Originator Servatus Biopharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Bacteria
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Rheumatoid arthritis
Most Recent Events
- 14 Oct 2021 Phase-I clinical trials in Rheumatoid arthritis in Australia (unspecified route) (Servatus Biopharmaceuticals pipeline, October 2021)